上皮性卵巢癌多药耐药基因的表达及其临床意义  

THE EXPRESSION AND CLINICAL SIGNIFICANCE OF MULTIDRUG RESISTANCE GENE IN EPITHELIAL OVARIAN CARCINOMA

作　　者：王言奎[1] 罗兵[1] 戴淑真[1] 刘东光 纪新强[1] 赵书鹏[1] 

机构地区：[1]青岛医学院

出　　处：《青岛医学院学报》1998年第3期172-174,共3页Acta Academiae Medicinae Qingdao Universitatis

基　　金：青岛市科委资助

摘　　要：目的探讨上皮性卵巢癌多药耐药（ＭＤＲ１）基因的表达及其临床意义。②方法利用逆转录聚合酶链反应（ＲＴ－ＰＣＲ）检测３３例初治上皮性卵巢癌病人肿瘤组织ＭＤＲ１基因表达情况，同时用ＭＴＴ比色法检测肿瘤细胞对抗癌药的敏感性。③结果１０例（３０．３％）卵巢癌病人ＭＤＲ１基因表达阳性。体外试验表明，ＭＤＲ１基因表达阳性卵巢癌细胞对多种抗癌药耐药，ＭＤＲ１基因的表达与卵巢癌细胞分化程度有关，但与病人的年龄、组织学类型及分期无关。Objective To study the expression and clinical significance of multidrug resistance(MDR1) gene in epithelial ovarian carcinoma. Methods In 33 primarily treated patients with epithelial ovarian carcinoma, the expression of MDR1 gene was detected using reverse transcription PCR (RTPCR). Sensitivity to the anticancer agents was also examined using the MTT assay. Results MDR1 gene was positive in 10(30. 3%) patients with ovarian carcinoma. Ovarian carcinoma cells with positive MDR1 gene expression showed cross drug resistance to various anticancer agents in vitro. The MDR1 gene expression and the differential grade of tumor cells was significantly correlated. But there was no confirmed relationship between MDR1 gene expression and the patients age, the pathologic type or the stage. Conclusion Detection of MDR1 gene expression in patients with ovarian carcinoma could be used as an index to predict the prognosis of the patients.

关 键 词：卵巢肿瘤 基因表达 上皮性 多药耐药基因 

分 类 号：R737.310.2[医药卫生—肿瘤]